Comments
Shares of Orchid Chemicals & Pharmaceuticals zoomed over 17 per cent today as the drug firm has received approval from the US health regulator for generic anti-bacterial Gemifloxacin Mesylate tablets.
Cheering the news, the stock soared 16.31 per cent to Rs 57.40 on the BSE. On the NSE, the scrip surged 17.15 per cent to Rs 57.70.
The company had received approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Gemifloxacin Mesylate tablets in the strength of 320 mg, Orchid Chemicals & Pharmaceuticals had said in a filing to the BSE yesterday.
The approval is with 180 days of generic drug exclusivity, it added.
Chennai-based Orchid Chemicals & Pharmaceuticals is present in segments like anti-infective, anti-inflammatory, central nervous system (CNS), cardio vascular segment (CVS), nutraceuticals and other oral and sterile products.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.